Humira once generated more annual revenue than the entire GDP of a small country. Then, in January 2023, the first biosimilar copies hit U.S. pharmacy shelves, and one of the most profitable drugs in pharmaceutical history began its long fade. AbbVie had seen it coming for years and spent billions preparing replacements. The question sitting inside today’s $257 share price is whether those replacements are merely good, or genuinely extraordinary, because the math embedded in that price demands the latter.
Here is the tension in a single breath: the stock trades at a price-to-sales ratio that sits in the 93rd percentile of AbbVie’s own decade-long range, according to our data. Meanwhile, net profit margins have spent most of the last five years in low single digits. High price, thin profits. Those two facts should not coexist unless the market is betting that margins are about to leap, and leap permanently.
The quick read
AbbVie’s filed revenues are growing again, up 8.6% in FY2025 and on track for roughly $67.6 billion in 2026, but reported net margins have been near zero for two consecutive fiscal years. The stock’s price-to-sales multiple sits near a decade high, which means the market is paying a premium price for a profit recovery that has not yet fully shown up in the filings. The open question is whether Skyrizi and Rinvoq can grow fast enough, and cleanly enough, to justify that premium before the next patent clock starts ticking.
How the old machine broke, and what replaced it
For a decade, Humira was AbbVie’s engine, a drug for rheumatoid arthritis and a dozen other conditions that at its peak brought in roughly $18.6 billion a year from U.S. sales alone. When biosimilar competition arrived in 2023, that engine didn’t stall, it shrank fast. Humira’s global revenues fell 49% in 2025, and by Q2 2026, U.S. quarterly sales had dropped to $756 million, a steep year-over-year decline recorded in the 10-Q for the quarter ended June 30, 2026. That is a business losing roughly a third of a major revenue line every twelve months.
The replacements, Skyrizi for skin and bowel diseases and Rinvoq for joints and more, are growing at a pace that has genuinely surprised observers. AbbVie now projects the two drugs will together generate roughly $31.6 billion in 2026, a figure that would have seemed implausible three years ago. Rinvoq’s U.S. patent exclusivity, secured through litigation settlements, now runs well into the late 2030s. That is a long runway, and it matters because patent life is the clock every pharmaceutical business races against.
For a saver trying to read this business, the core fact is that AbbVie successfully swapped one blockbuster for two, but the transition left visible scars in the profit line, and the market’s current price assumes the scars heal completely.
What the filings actually show
Revenue tells an optimistic story. The FY2025 10-K shows full-year net revenues of $61.2 billion, up 8.6% from the prior year, and management has since raised its 2026 revenue guidance to approximately $67.6 billion, according to the Q2 2026 earnings release. Q2 2026 alone brought in nearly $17 billion in worldwide net revenues, with a GAAP operating margin well above a third of sales.
Reported net margins tell a harder story. Our data shows net margins near zero for two consecutive fiscal years before a modest recovery in FY2025. The gap between a strong operating margin in a single quarter and a thin full-year net margin reflects the weight of interest costs, acquisition charges, and one-time items that sit below the operating line. This is not unusual for a company that has spent heavily on deals, but it does mean the earnings-per-share figure that drives the headline price-to-earnings ratio is fragile. Our data puts the trailing P/E at 242 times, which is in the 42nd percentile of AbbVie’s own decade range, meaning the market has sometimes paid even more relative to reported earnings. The price-to-sales ratio, however, is near a decade high.
R&D spending reached $9.1 billion in FY2025, more than the company’s entire reported net income for the year, which tells you where management is betting the next decade’s profits will come from.
The pipeline as the argument
AbbVie’s price is not really a bet on what the company earns today. It is a bet on what the pipeline delivers. On that front, 2026 has produced real evidence. The FDA approved Skyrizi for pediatric use in psoriatic disease on June 26, 2026, opening a new patient population. In oncology, the AbbVie newsroom reported positive Phase 3 results for etentamig in multiple myeloma, showing a 74% objective response rate, a meaningful number in a disease where options are limited. The company also reported that atogepant, its migraine drug, beat placebo in a menstrual migraine prevention trial, with regulatory submissions planned, according to the September 10, 2026 AbbVie newsroom release.
These are not speculative early-stage results. They are late-stage readouts and regulatory decisions, the kind that convert pipeline into revenue. Whether they convert fast enough, and at sufficient scale, to justify the current price-to-sales multiple is the question the filings cannot yet answer.
The Apogee Therapeutics acquisition, a deal worth nearly $11 billion, adds a wrinkle. It trimmed full-year adjusted earnings guidance modestly, even as the underlying business overperformed. Analysts tracked by MarketBeat project adjusted earnings recovering meaningfully over the next two years, suggesting the dilution is seen as temporary. But temporary dilution from a large acquisition is a claim that requires execution to prove.
The dividend as a floor, and a constraint
AbbVie declared a quarterly dividend of $1.73 per share on September 10, 2026, payable November 16, bringing the annualized payout to $6.92. The company has raised its dividend every year since its 2013 spinoff from Abbott, a streak that earns it a place in the S&P Dividend Aristocrats. At the current share price, that is a yield approaching 3%, modest by income standards but backed by a business generating several billion dollars in free cash flow each quarter.
The dividend is also a constraint. A company committed to annual increases must grow earnings to keep the payout ratio manageable. Forward estimates project the ratio falling to a comfortable level on next year’s earnings. But that comfort depends on the earnings recovery arriving on schedule. If pipeline execution slips or acquisition costs run higher than modeled, the dividend commitment tightens the room to maneuver.
Reading the numbers
- $67.6 billion, full-year 2026 revenue guidance (raised from $67.3 billion at the start of the year, per the Q2 2026 summary): this is what management now expects to collect from customers this year. It is roughly 10% more than FY2025’s filed $61.2 billion. A household analogy: if a family earned $61,000 last year and expected $67,600 this year, that would be a meaningful raise, but only if the bills didn’t grow faster. For AbbVie, the bill is R&D, interest, and acquisition costs.
- P/S ratio of 7.2, at the 93rd percentile of its own decade (our data): the price-to-sales ratio is what investors pay for each dollar of annual revenue. At 7.2 times, the market is paying $7.20 for every $1 AbbVie collects. The company’s own median over the past decade is $5.20. Paying above your own historical average is a bet that the future is better than the past average, not just better than today.
- $31.6 billion projected from Skyrizi and Rinvoq in 2026 (per patent and guidance disclosures): two drugs replacing one. Humira at its peak earned roughly $18.6 billion in the U.S. alone. The two successors are now projected to earn $31.6 billion combined globally. That is a larger number, but it is also two drugs instead of one, meaning the concentration risk has shifted rather than disappeared.
- 74% objective response rate for etentamig in multiple myeloma (Phase 3 results, per the AbbVie newsroom): in a disease where many patients have exhausted other options, roughly three in four patients responded to the drug. That is a strong clinical result. Whether it translates to commercial scale depends on pricing, competition, and label breadth, none of which the trial data can confirm.
- Trailing P/E of 242 times, our data: for every dollar of reported earnings over the past year, the market is paying $242. A more graspable version: if a small business earned $1,000 last year and someone offered to buy it for $242,000, they would need to believe profits are about to multiply dramatically. That is the implicit bet in today’s price.
If AbbVie’s revenue grows toward filed guidance and margins recover toward the operating-line levels already visible in Q2 2026, our data’s decade-median price-to-sales multiple would place the stock meaningfully below today’s price. If margins recover faster than the filed trend implies, the current price-to-sales premium finds more support. The data cannot resolve which path arrives first, and that uncertainty is precisely what the gap between the math and the mood contains.
For the standing yardsticks on Abbvie: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Abbvie.
Sources
- AbbVie 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- AbbVie 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- AbbVie Q2 2026 earnings 8-K (StockTitan)
- AbbVie Q2 2026 earnings summary (VectorShift)
- AbbVie FY2025 full-year results press release (PR Newswire)
- AbbVie quarterly dividend declaration, September 10, 2026 (AbbVie newsroom)
- Skyrizi pediatric FDA approval, June 26, 2026 (AbbVie newsroom)
- AbbVie newsroom (etentamig Phase 3 results and atogepant trial data)
- Humira biosimilar competition analysis (BiosimilarsRR)
- AbbVie analyst consensus and price targets (MarketBeat)
